The anticancer activity of the compounds was tested on two MDR models comprised of P-gp overexpressing cancer cell lines established after continuous exposure to paclitaxel (PTX) or doxorubicin (DOX) [16,17] and their corresponding sensitive counterparts. Here, PGP is linked to cancer.